PolyActiva Commences Clinical Trial of Biodegradable Ocular Implant for Glaucoma
Clinical Trial Begins For PolyActiva Biodegradable Glaucoma Implant. PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently received USD$12million in venture capital to fund its Phase 1 Clinical Trial which will evaluate the safety and tolerability of its PA5108 ocular implant designed to biodegrade after the treatment period.
Sustained Drug Delivery for Glaucoma Treatment – An Update from the American Glaucoma Society (AGS) 2017 Annual Meeting
Caution — INVESTIGATIONAL DEVICEs, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE. These products have not been approved by the FDA as safe or effective. Anyone who has glaucoma is likely to desire a treatment other than eye drops. Currently...Could a New Class of Glaucoma Medications Be Around The Corner?
An exciting new class of potential glaucoma medications include what are termed the ROCK and ROCK/NET inhibitors. And it’s about time! Twenty years have passed since the last new class of medications (prostaglandin analogs) were approved for the treatment of glaucoma.
